There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on HCA Healthcare (HCA – Research Report), VolitionRX (VNRX – Research Report) and Pharming Group (PHAR – Research Report) with bullish sentiments.
HCA Healthcare (HCA)
RBC Capital analyst Ben Hendrix reiterated a Buy rating on HCA Healthcare today and set a price target of $283.00. The company’s shares closed last Thursday at $252.26.
According to TipRanks.com, Hendrix is a 1-star analyst with an average return of
HCA Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $283.22, implying a 15.7% upside from current levels. In a report issued on March 13, Stephens also reiterated a Buy rating on the stock with a $283.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Pharming Group (PHAR)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Pharming Group, with a price target of $37.00. The company’s shares closed last Thursday at $11.34.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of
Pharming Group has an analyst consensus of Moderate Buy, with a price target consensus of $37.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HCA:
- HCA Healthcare price target raised to $257 from $235 at JPMorgan
- HCA Healthcare price target raised to $285 from $260 at Argus
- HCA Healthcare exec Berres sells 4,000 common shares
- HCA Healthcare price target raised to $300 from $230 at Raymond James
- HCA Healthcare price target raised to $285 from $240 at Loop Capital
